Validation of a DNA methylation HPV triage classifier in a screening sample-Reference-Cited by-同舟云学术

Validation of a DNA methylation HPV triage classifier in a screening sample

Published:2016-02-08 Issue:11 Volume:138 Page:2745-2751
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Lorincz Attila T.¹,Brentnall Adam R.¹,Scibior-Bentkowska Dorota¹,Reuter Caroline¹,Banwait Rawinder¹,Cadman Louise¹,Austin Janet¹,Cuzick Jack¹,Vasiljević Natasa¹

Affiliation:

1. Queen Mary University of London, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine; Charterhouse Square London EC1M 6BQ United Kingdom

Funder

Cancer Research UK

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis;Sanjose;Lancet Infect Dis,2007

2. Human papillomavirus and Papanicolaou tests to screen for cervical cancer;Naucler;N Engl J Med,2007

3. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial;Bulkmans;Lancet,2007

4. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial;Rijkaart;Lancet Oncol,2011

5. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial;Kitchener;Lancet Oncol,2009

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA methylation at individual CpG-sites of EPB41L3, HTERT and FAM19A4 are useful for detection of cervical high-grade squamous intraepithelial lesions (HSIL) or worse: Analysis of individual CpG-sites outperforms averaging;Tumour Virus Research;2024-12

2. Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer;Vaccine;2024-11

3. Triage performance of PAX1m/JAM3m in opportunistic cervical cancer screening of non‒16/18 human papillomavirus-positive women: a multicenter prospective study in China;Clinical Epigenetics;2024-08-16

4. Low methylation marker levels among human papillomavirus‐vaccinated women with cervical high‐grade squamous intraepithelial lesions;International Journal of Cancer;2024-05-27

5. Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries;Clinical Epigenetics;2024-04-20